These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35062716)

  • 21. COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.
    Ramos L; Carrillo-Palau M; Alonso-Abreu I; Reygosa C; Hernández-Alvarez N; Amaral C; Hernández A; Benítez-Zafra F; Pérez-González F; Quintana-Díaz H; Hernandez-Guerra M
    Gastroenterol Hepatol; 2023 Apr; 46(4):255-260. PubMed ID: 35609791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients.
    Andrade P; Santos-Antunes J; Rodrigues S; Lopes S; Macedo G
    J Gastroenterol Hepatol; 2015 Nov; 30(11):1591-5. PubMed ID: 25967740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
    Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation.
    Lev-Tzion R; Focht G; Lujan R; Mendelovici A; Friss C; Greenfeld S; Kariv R; Ben-Tov A; Matz E; Nevo D; Barak-Corren Y; Dotan I; Turner D
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):e1263-e1282. PubMed ID: 34954338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study.
    Atia O; Shavit-Brunschwig Z; Mould DR; Stein R; Matar M; Aloi M; Ledder O; Focht G; Urlep D; Hyams J; Broide E; Weiss B; Levine J; Russell RK; Turner D
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):31-42. PubMed ID: 36306803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan.
    Miyazaki H; Watanabe D; Ito Y; Okamoto N; Tokunaga E; Ku Y; Ooi M; Hoshi N; Kodama Y
    Dig Dis Sci; 2023 Feb; 68(2):564-570. PubMed ID: 36178566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
    Alrashed F; Abdullah I; Alfadhli A; Shehab M
    Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
    [No Abstract]   [Full Text] [Related]  

  • 29. COVID-19 Vaccine Hesitancy Among Patients with Inflammatory Bowel Diseases at a Diverse Safety Net Hospital.
    Herman HS; Rosenthaler MP; Elhassan N; Weinberg JM; Satyam VR; Wasan SK
    Dig Dis Sci; 2022 Nov; 67(11):5029-5033. PubMed ID: 35175432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials.
    Shehab M; Alrashed F; Alkazemi A; Lakatos PL; Bessissow T
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):469-477. PubMed ID: 36961082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY.
    Krugliak Cleveland N; Ghosh S; Chastek B; Bancroft T; Candela N; Fan T; Umashankar K; Rubin DT
    Inflamm Bowel Dis; 2024 Oct; 30(10):1776-1787. PubMed ID: 37921344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postvaccination Symptoms After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease: A Prospective, Comparative Study.
    Mujukian A; Kumar R; Li D; Debbas P; Botwin GJ; Cheng S; Ebinger J; Braun J; McGovern D; Melmed GY;
    Inflamm Bowel Dis; 2024 Apr; 30(4):602-616. PubMed ID: 37556401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study.
    Shehab M; Abu-Farha M; Alrashed F; Alfadhli A; Alotaibi K; Alsahli A; Alphonse Thanaraj T; Channanath A; Ali H; Abubaker J; Almulla F
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Gu P; Luo J; Kim J; Paul P; Limketkai B; Sauk JS; Park S; Parekh N; Zheng K; Rudrapatna V; Syal G; Ha C; McGovern DP; Melmed GY; Fleshner P; Eisenstein S; Ramamoorthy S; Dulai PS; Boland BS; Grunvald E; Mahadevan U; Ohno-Machado L; Sandborn WJ; Singh S
    Am J Gastroenterol; 2022 Oct; 117(10):1639-1647. PubMed ID: 35973139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination.
    Caldera F; Farraye FA; Necela BM; Cogen D; Saha S; Wald A; Daoud ND; Chun K; Grimes I; Lutz M; Van Helden SR; Swift MD; Virk A; Bharucha AE; Patel TC; Gores GJ; Chumsri S; Hayney MS; Knutson KL
    Inflamm Bowel Dis; 2023 Aug; 29(8):1202-1209. PubMed ID: 36103273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease.
    Sahyoun LC; Fetene J; McMillan C; Protiva P; Al Bawardy B; Gaidos JKJ; Proctor D
    Dig Dis Sci; 2024 May; 69(5):1654-1660. PubMed ID: 38466459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
    BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 Vaccination in Inflammatory Bowel Disease (IBD).
    Kubas A; Malecka-Wojciesko E
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study.
    Hahn GD; LeBlanc JF; Golovics PA; Wetwittayakhlang P; Qatomah A; Wang A; Boodaghians L; Liu Chen Kiow J; Al Ali M; Wild G; Afif W; Bitton A; Lakatos PL; Bessissow T
    World J Gastroenterol; 2022 Sep; 28(33):4823-4833. PubMed ID: 36156919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.